3SBio Sees More Business Development Deals
Tony He, CFO of the Chinese biopharmaceutical firm 3SBio, discusses his outlook for dealmaking and the progress of a record…
Tag: 3SBio
3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO bid
Mandi, the Alibaba Health-backed consumer healthcare arm being spun off from mainland drug maker 3SBio, filed for an initial public…
Pfizer Licenses 3SBio Cancer Drug for Record $1.2 Billion
Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores…